[1]庄伟 王志强 王正杰 安淑华.利拉鲁肽对2型糖尿病患者血清miRNA表达及相关细胞信号通路蛋白的影响[J].国际内分泌代谢杂志,2022,42(04):307-311.[doi:10.3760/cma.j.cn121383-20220218-02038]
　Zhuang Wei,Wang Zhiqiang,Wang Zhengjie,et al.Effects of liraglutide on miRNAs expression profile and related cell signaling pathways in T2DM patients[J].International Journal of Endocrinology and Metabolism,2022,42(04):307-311.[doi:10.3760/cma.j.cn121383-20220218-02038]
点击复制

利拉鲁肽对2型糖尿病患者血清miRNA表达及相关细胞信号通路蛋白的影响()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
42
期数:
2022年04期
页码:
307-311
栏目:
论著
出版日期:
2022-07-20

文章信息/Info

Title:
Effects of liraglutide on miRNAs expression profile and related cell signaling pathways in T2DM patients
作者:
庄伟1 王志强1 王正杰1 安淑华2
1唐山市人民医院药剂科 063300; 2唐山市人民医院内分泌科 063300
Author(s):
Zhuang Wei1;  Wang Zhiqiang1;  Wang Zhengjie1;  An Shuhua2.
1Department of Pharmacy, Tangshan People's Hospital, Tangshan 063300, China; 2Department of Endocrinology, Tangshan People's Hospital, Tangshan 063300, China
关键词:
利拉鲁肽;  细胞信号通路;  2型糖尿病;  miRNAs
Keywords:
Liraglutide;  Cell signaling pathway;  Type 2 diabetes mellitu;  miRNAs
DOI:
10.3760/cma.j.cn121383-20220218-02038
摘要:
目的 探讨利拉鲁肽对2型糖尿病(T2DM)患者血清miRNA表达谱及相关细胞信号通路蛋白水平的影响。方法 选取唐山市人民医院于2020年10月至2021年10月期间收治的26例T2DM患者,均接受利拉鲁肽治疗,所有患者持续治疗3个月,比对治疗前后血清miRNA变化情况,采用Pearson相关分析hsa-miR29a-3p变化值与血清基质金属蛋白酶9(MMP-9)、转化生长因子(TGF)-β1变化值的相关性。对治疗前后表达水平变化差异显著的miRNA行基因本体论(GO)和KEGG通路富集分析,以及miRNA-mRNA网络分析。结果 治疗后患者的糖化血红蛋白A1c(HbAlc)、空腹血糖(FPG)、甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白-胆固醇(LDL-C)、MMP-9以及TGF-β1水平均明显降低,而高密度脂蛋白-胆固醇(HDL-C)水平明显增加(P均<0.05)。治疗后hsa-miR1-3p、hsa-miR21-5p、hsa-miR29a-3p、hsa-miR30c-5p、hsa-miR133a-5p、hsa-miR500-5p、hsa-mi6806-5p均明显降低(P均<0.05),其中hsa-miR29a-3p降低程度最明显(P<0.001)。Pearson相关分析显示hsa-miR29a-3p变化值与MMP-9、TGF-β1变化值均呈正相关(r=0.638,0.586),差异有统计学意义(P均<0.05)。GO分析结果显示:胶原分解代谢过程、轴突延伸以及细胞黏附占生物过程前3位。细胞组分中内质网腔、突触后密度以及细胞连接占据前3位。分子功能中Rho GTPase结合、细胞外基质结构成分、磷脂酰肌醇3磷酸结合占据前3位。KEGG分析显示:差异表达基因主要富集于晚期糖基化终末产物受体信号通路、肿瘤坏死因子信号通路、Wnt信号通路(P均<0.05)。miRNA-mRNA网络分析显示差异表达miRNA对应244个靶基因mRNA。结论 T2DM患者经利拉鲁肽治疗后,血清hsa-miR29a-3p等与炎症、胶原分解代谢过程相关的miRNA表达下调,可能有利于减少患者心肌纤维化。
Abstract:
Objective To investigate the effects of liraglutide on serum miRNA expression profiles and related cell signaling pathways in patients with type 2 diabetes mellitus(T2DM).Methods A total of 26 T2DM patients admitted to Tangshan People's Hospital from October 2020 to October 2021 were selected, all received liraglutide treatment for 3 months. The changes of serum miRNA before and after treatment were compared, and the correlation between the changes of hsa-miR29a-3p and the changes of MMP-9 and TGF-β1 were analyzed by Pearson correlation. Gene ontology(GO)and KEGG pathway enrichment analysis, and miRNA-mRNA network analysis were performed for miRNAs with significant differences.Results After treatment, the levels of HbAlc, FPG, TG, TC, LDL-C, MMP-9, and TGF-β1 were significantly decreased, while the level of HDL-C was significantly increased(all P<0.05). After treatment, hsa-miR1-3p, hsa-miR21-5p, hsa-miR29a-3p, hsa-miR30c-5p, hsa-miR133a-5p, hsa-miR500-5p, and hsa-mi6806-5p were significantly decreased(all P<0.05), among which hsa-miR29a-3p decreased most significantly(P<0.001). Pearson correlation analysis showed that the change of hsa-miR29a-3p was positively correlated with the changes of MMP-9 and TGF-β1(r=0.638, 0.586), and the difference were statistically significant(all P<0.05). The results of GO analysis showed that collagen catabolism, axon extension and cell adhesion accounted for the top three biological processes. The endoplasmic reticulum lumen, postsynaptic density, and cell junctions occupied the top three positions in cellular components. Among the molecular functions, Rho GTPase binding, extracellular matrix structural components, and phosphatidylinositol 3 phosphate binding occupied the first three positions. KEGG analysis showed that the differentially expressed genes were mainly enriched in the advanced glycation end product receptor signaling pathway, tumor necrosis factor signaling pathway and Wnt signaling pathway in diabetic complications(all P<0.05). miRNA-mRNA network analysis showed that the differentially expressed miRNAs corresponded to 244 target gene mRNAs.Conclusion Liraglutide can affect the expressions of serum hsa-mir29a-3p and other miRNAs related to inflammation and collagen catabolism, which may be beneficial to reduce myocardial fibrosis in T2DM patients.

参考文献/References:

[1] 贠菊平,裴雨晴,谷清.老年2型糖尿病患者用药特点分析[J].中国临床药理学杂志,2021,37(3):315-317.DOI:10.13699/j.cnki.1001-6821.2021.03.027.
[2] Dalsgaard NB,Gasbjerg LS,Hansen LS,et al.The role of GLP-1 in the postprandial effects of acarbose in type 2 diabetes[J].Eur J Endocrinol,2021,184(3):383-394.DOI:10.1530/EJE-20-1121.
[3] 高妍.利拉鲁肽对心血管系统的保护作用[J].中华内分泌代谢杂志,2013,29(10):917-920.DOI:10.3760/cma.j.issn.1000-6699.2013.10.024.
[4] Marso SP,Daniels GH,Brown-Frandsen K,et al.Liraglutide and cardiovascular outcomes in type 2 diabetes[J].N Engl J Med,2016,375(4):311-322.DOI:10.1056/NEJMoa1603827.
[5] Bielska A,Niemira M,Kretowski A.Recent highlights of research on miRNAs as early potential biomarkers for cardiovascular complications of type 2 diabetes mellitus[J].Int J Mol Sci,2021,22(6):3153.DOI:10.3390/ijms22063153.
[6] Prattichizzo F,Matacchione G,Giuliani A,et al.Extracellular vesicle-shuttled miRNAs:a critical appraisal of their potential as nano-diagnostics and nano-therapeutics in type 2 diabetes mellitus and its cardiovascular complications[J].Theranostics,2021,11(3):1031-1045.DOI:10.7150/thno.51605.
[7] 中华医学会糖尿病学分会.中国2型糖尿病防治指南(2020年版)[J].中华糖尿病杂志,2021,13(4):315-409.DOI:10.3760/cma.j.cn115791-20210221-00095.
[8] 唐鑫汇,李莉.糖尿病患者胰岛素注射及血糖监测恐惧的研究进展[J].中华护理杂志,2020,55(6):952-956.DOI:10.3761/j.issn.0254-1769.2020.06.031.
[9] Tamborlane WV,Barrientos-Pérez M,Fainberg U,et al.Liraglutide in children and adolescents with type 2 diabetes[J].N Engl J Med,2019,381(7):637-646.DOI:10.1056/NEJMoal903822.
[10] Zhang J,Xu H,Gong L,et al.MicroRNA-132 protects H9c2 cells against oxygen and glucose deprivation-evoked injury by targeting FOXO3A[J].J Cell Physiol,2020,235(1):176-184.DOI:10.1002/jcp.28956.
[11] Li Q,Kim YR,Vikram A,et al.P66Shc-induced MicroRNA-34a causes diabetic endothelial dysfunction by downregulating sirtuin1[J].Arterioscler Thromb Vasc Biol,2016,36(12):2394-2403.DOI:10.1161/ATVBAHA.116.308321.
[12] 段卡丹,张守彦,李松森,等.MAPK信号通路在转化生长因子β1诱导心肌成纤维细胞趋化运动中的作用[J].中国动脉硬化杂志,2020,28(11):966-971.DOI:10.3969/j.issn.1007-3949.2020.11.009.
[13] 张冠军,张巍,王开成,等.厄贝沙坦对糖尿病大鼠心肌纤维化中基质金属蛋白酶通路及相关因子的影响[J].中国糖尿病杂志,2017,25(12):1124-1128.DOI:10.3969/j.issn.1006-6187.2017.12.014.
[14] 郑晓茂,茹琴,陈琳.晚期糖基化终产物对糖尿病及其并发症的影响和干预的研究进展[J].重庆医学,2019,48(13):2292-2296.DOI:10.3969/j.issn.1671-8348.2019.13.033.

相似文献/References:

[1]刘璠,张趁儒,周慧敏,等.2型糖尿病患者利拉鲁肽替代预混胰岛素治疗的有效性和安全性分析[J].国际内分泌代谢杂志,2014,(04):237.[doi:10.3760/cma.j.issn.1673-4157.2014.04.006]
　Liu Fan,Zhang Chenru,Zhou Huimin,et al.Efficacy and safety of liraglutide switched from premixed insulin in patients with type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2014,(04):237.[doi:10.3760/cma.j.issn.1673-4157.2014.04.006]
[2]孟旭英,范振迁,郭剑超.利拉鲁肽与格列美脲治疗2型糖尿病的系统评价[J].国际内分泌代谢杂志,2016,36(06):380.[doi:10.3760/cma.j.issn.1673-4157.2016.06.05]
　Meng Xuying,Fan Zhenqian,Guo Jianchao..Effects of liraglutide versus glimepiride for type 2 diabetes mellitus: a systematic review[J].International Journal of Endocrinology and Metabolism,2016,36(04):380.[doi:10.3760/cma.j.issn.1673-4157.2016.06.05]
[3]陈妹妹,梁瑜祯,李争明,等.利拉鲁肽对白色脂肪的作用[J].国际内分泌代谢杂志,2020,40(05):331.[doi:10.3760/cma.j.cn121383-20191206-12014]
　Chen Meimei,Liang Yuzhen,Li Zhengming,et al.Effect of liraglutide on white fat[J].International Journal of Endocrinology and Metabolism,2020,40(04):331.[doi:10.3760/cma.j.cn121383-20191206-12014]

备注/Memo

备注/Memo:
通信作者:庄伟,Email:52258921@qq.com
更新日期/Last Update: 2022-06-20